-
Barclays: Mallinckrodt's Sucampo Deal Overshadowed By Competitive Threats
Friday, February 2, 2018 - 5:01pm | 473Read More...Mallinckrodt PLC (NYSE: MNK) agreed to buy Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) in a deal announced in December. The Analyst Weighing in the planned acquisition, Barclays analyst Douglas Tsao downgraded shares of Mallinckrodt from Equal Weight to Underweight and lowered the price...
-
Oppenheimer Suggests Buying Mallinckrodt On FTC Investigation Inspired Weakness
Thursday, January 19, 2017 - 1:12pm | 303Read More...Oppenheimer remains Outperform-rated on Mallinckrodt PLC (NYSE: MNK) saying near-term concerns over Acthar competition are overblown, as he expressed confidence in Acthar's durability. The brokerage, which has a $72 price target on Mallinckrodt shares, said the company’s key brands,...
-
Mallinckrodt Reports Better-Than-Expected Q1, Raises Guidance
Tuesday, February 2, 2016 - 8:54am | 263Read More...Shares of Mallinckrodt PLC (NYSE: MNK) were trading higher by nearly 6 percent early Tuesday morning after the company reported its first quarter results. Mallinckrodt earned $2.09 per share in the first quarter on revenue of $914.80 million. Wall Street analysts were expecting the company to...
